Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 3Recruiting 2Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Head and Neck Neoplasms 276Squamous Cell Carcinoma of Head and Neck 241Carcinoma, Non-Small-Cell Lung 86Melanoma 68Neoplasms 61Colorectal Neoplasms 52Neoplasm Metastasis 48Carcinoma, Squamous Cell 48Thyroid Neoplasms 47Breast Neoplasms 41Carcinoma, Renal Cell 36Lung Neoplasms 34Ovarian Neoplasms 33Oropharyngeal Neoplasms 30Stomach Neoplasms 29Mouth Neoplasms 29Nasopharyngeal Carcinoma 28Triple Negative Breast Neoplasms 26Uterine Cervical Neoplasms 25Sarcoma 25Laryngeal Neoplasms 24Pancreatic Neoplasms 23Esophageal Neoplasms 23Salivary Gland Neoplasms 21Urinary Bladder Neoplasms 20Recurrence 19Nasopharyngeal Neoplasms 18Small Cell Lung Carcinoma 17Carcinoma, Transitional Cell 17Prostatic Neoplasms 16

Interventions

pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Otorhinolaryngologic Diseases × Head & Neck × Clear all
NCT03769467 2024-11-14

Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)

Atara Biotherapeutics

Phase 1/2 Terminated
12 enrolled 8 charts
Head & Neck

Nasopharyngeal Carcinoma, Carcinoma, Head and Neck Neoplasms, Stomatognathic Diseases, Nasopharyngeal Diseases, Nasopharyngeal Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Nose Neoplasms, Otorhinolaryngologic Diseases, Otorhinolaryngologic Neoplasms, Pharyngeal Diseases, Pharyngeal Neoplasms, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡